Skewed China birth rate to leave 24 million men single
By Agence France Presse,
Agence France Presse
| 01. 11. 2010
More than 24 million Chinese men of marrying age could find themselves without spouses in 2020, state media reported on Monday, citing a study that blamed sex-specific abortions as a major factor.
The study, by the government-backed Chinese Academy of Social Sciences, named the gender imbalance among newborns as the most serious demographic problem for the country's population of 1.3 billion, the Global Times said.
"Sex-specific abortions remained extremely commonplace, especially in rural areas," where the cultural preference for boys over girls is strongest, the study said, while noting the reasons for the gender imbalance were "complex."
Researcher Wang Guangzhou said the skewed birth ratio could lead to difficulties for men with lower incomes in finding spouses, as well as a widening age gap between partners, according to the Global Times.
Another researcher quoted by the newspaper, Wang Yuesheng, said men in poorer parts of China would be forced to accept marriages late in life or remain single for life, which could "cause a break in family lines."
"The chance of getting married will be rare if a man is...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...